Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Yen-Cheng Chen, Cheng-Jen Ma, Ching-Chun Li, Wei-Chih Su, Po-Jung Chen, Tian-Lu Cheng, Tzu-Chieh Yin, Ching-Wen Huang, Tsung-Kun Chang, Hsiang-Lin Tsai, Kuo-Hsiang Chuang, Jaw-Yuan Wang
Publikováno v:
Oncology Research
Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecan-induced diarrhea is intestinal muco
Autor:
Yi-Ting Chen, Cheng-Jen Ma, Wei-Chih Su, Hsiang-Lin Tsai, Ching-Wen Huang, Jaw-Yuan Wang, Yung-Sung Yeh, Wen-Hung Hsu, Fang-Jung Yu, Tsung-Kun Chang
Publikováno v:
Oncology Research
This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with s
Autor:
AnnaMaria Grosso, Giandomenico Roviello, Daniele Lavacchi, I. Landini, Gabriele Perrone, Stefania Nobili, Enrico Mini, Roberto Mazzanti, Giulio Vicini, Carmine Santomaggio, Renato Tassi
Publikováno v:
Oncology Research
The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectab
Autor:
Rao Xin, Xiuhua Weng, Meiyue Li, Shen Lin, Lixian Zhong, Shaohong Luo, Xiongwei Xu, Pinfang Huang
Publikováno v:
Oncology Research
To evaluate the cost‐utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and
Autor:
Hisayo Doi, Hiroshi Matsuoka, Daisuke Makiura, Junichiro Inoue, Takashi Saito, Rei Ono, Yoshitada Sakai, Atsuo Okamura, Kimikazu Yakushijin
Publikováno v:
Oncology Research
Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN hav
Autor:
Hiroki Nakahara, Kentaro Ito, Osamu Hataji, Atsushi Fujiwara, Esteban C. Gabazza, Corina N. D’Alessandro-Gabazza, Hajime Fujimoto, Osamu Taguchi, Taro Yasuma, Masamichi Yoshida, Tetsu Kobayashi, Kota Nishihama
Publikováno v:
Oncology Research
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (g
Autor:
Jiang Chuner, Liu Tongxin, Yan Fengqin, Wang Fangzheng, Fu Zhenfu, Ye Zhiming, Li Bin, Qin Weifeng, Hu Fujun, Chen Ming, Wang Lei
Publikováno v:
Oncology Research
In this retrospective review of a single institution’s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopha
Autor:
Cheng-Jen Ma, I-Chen Wu, Ching-Wen Huang, Jaw-Yuan Wang, Yung-Sung Yeh, Huang-Ming Hu, Hsiang-Lin Tsai, Tian-Lu Cheng
Publikováno v:
Oncology Research
We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyp
Publikováno v:
Oncology Research
We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line t
Autor:
Shaesta Mehta, Arvind Sahu, Prachi Patil, Vijay Patil, Nilendu Purandare, Srushti Shah, Nirmala A. Jambhekar, Sarbani Ghosh-Laskar, Dipti Nakti, Kumar Prabhash, Abhishek Mahajan, Vanita Noronha, Sanjay Talole, Amit Joshi
Publikováno v:
Oncology Research
There are little data on the efficacy and safety of taxane/platinum with definitive radiotherapy (RT) for esophageal/GEJ cancer. This article is a retrospective analysis of patients who received weekly paclitaxel 50 mg/m2 and carboplatin AUC 2 with r